HSP90AA1 promotes lymphatic metastasis of hypopharyngeal squamous cell carcinoma by regulating epithelial-mesenchymal transition.
Humans
Squamous Cell Carcinoma of Head and Neck
/ genetics
Carcinoma, Squamous Cell
/ pathology
Epithelial-Mesenchymal Transition
/ genetics
Lymphatic Metastasis
Prognosis
Head and Neck Neoplasms
/ genetics
Cell Line, Tumor
Cell Proliferation
/ genetics
Cell Movement
/ genetics
Gene Expression Regulation, Neoplastic
HSP90 Heat-Shock Proteins
/ genetics
EMT
HNSCC
HSP90AA1
Hypopharyngeal squamous cell carcinoma
Lymphatic metastasis
Journal
Oncology research
ISSN: 1555-3906
Titre abrégé: Oncol Res
Pays: United States
ID NLM: 9208097
Informations de publication
Date de publication:
2023
2023
Historique:
received:
22
03
2023
accepted:
24
05
2023
medline:
8
8
2023
pubmed:
7
8
2023
entrez:
7
8
2023
Statut:
epublish
Résumé
Lymphatic metastasis (LM) emerges as an independent prognostic marker for hypopharyngeal squamous cell carcinoma (HSPSCC), chiefly contributing to treatment inefficacy. This study aimed to scrutinize the prognostic relevance of HSP90AA1 and its potential regulatory mechanism of concerning LM in HPSCC. In a preceding investigation, HSP90AA1, a differential gene, was discovered through transcriptome sequencing of HPSCC tissues, considering both the presence and absence of LM. Validation of HSP90AA1 expression was accomplished via qRT-PCR, western-blotting(WB), and immunohistochemistry(IHC), while its prognostic significance was assessed employing Kaplan-Meier survival analysis(KMSA), log-rank test(LR), and Cox's regression analysis(CRA). Bioinformatics techniques facilitated the prediction and analysis of its plausible mechanisms in LM, further substantiated by HSP90AA1 is substantially up-regulated in HPSCC with LM and is identified as an independent prognostic risk determinant. The down-regulation of HSP90AA1 can achieve inhibition of tumor cell proliferation, migration and invasion. Both HSP90AA1, by controlling EMT, can foster LM in HPSCC.This finding sets the foundation for delving into new therapeutic targets for HPSCC.
Sections du résumé
Background
UNASSIGNED
Lymphatic metastasis (LM) emerges as an independent prognostic marker for hypopharyngeal squamous cell carcinoma (HSPSCC), chiefly contributing to treatment inefficacy. This study aimed to scrutinize the prognostic relevance of HSP90AA1 and its potential regulatory mechanism of concerning LM in HPSCC.
Methods
UNASSIGNED
In a preceding investigation, HSP90AA1, a differential gene, was discovered through transcriptome sequencing of HPSCC tissues, considering both the presence and absence of LM. Validation of HSP90AA1 expression was accomplished via qRT-PCR, western-blotting(WB), and immunohistochemistry(IHC), while its prognostic significance was assessed employing Kaplan-Meier survival analysis(KMSA), log-rank test(LR), and Cox's regression analysis(CRA). Bioinformatics techniques facilitated the prediction and analysis of its plausible mechanisms in LM, further substantiated by
Results
UNASSIGNED
HSP90AA1 is substantially up-regulated in HPSCC with LM and is identified as an independent prognostic risk determinant. The down-regulation of HSP90AA1 can achieve inhibition of tumor cell proliferation, migration and invasion. Both
Conclusions
UNASSIGNED
HSP90AA1, by controlling EMT, can foster LM in HPSCC.This finding sets the foundation for delving into new therapeutic targets for HPSCC.
Identifiants
pubmed: 37547757
doi: 10.32604/or.2023.030081
pii: 30081
pmc: PMC10398399
doi:
Substances chimiques
HSP90AA1 protein, human
0
HSP90 Heat-Shock Proteins
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
787-803Informations de copyright
© 2023 Tang et al.
Déclaration de conflit d'intérêts
The authors declare that they have no conflicts of interest to report regarding the present study.
Références
J Transl Med. 2022 Jun 6;20(1):255
pubmed: 35668458
Clin Cancer Res. 2009 Jan 1;15(1):9-14
pubmed: 19118027
Cancer Lett. 2013 Jul 28;335(2):270-7
pubmed: 23438693
Cell. 2011 Oct 14;147(2):275-92
pubmed: 22000009
CA Cancer J Clin. 2021 Jan;71(1):7-33
pubmed: 33433946
Cancer. 2016 Dec 1;122(23):3624-3631
pubmed: 27479645
Drug Resist Updat. 2009 Feb-Apr;12(1-2):17-27
pubmed: 19179103
J Laryngol Otol. 2018 May;132(5):385-400
pubmed: 29891019
Clin Otolaryngol. 2020 Jan;45(1):73-82
pubmed: 31660699
Curr Pharm Des. 2013;19(3):347-65
pubmed: 22920906
Sci Rep. 2019 Nov 11;9(1):16420
pubmed: 31712650
Comput Struct Biotechnol J. 2021 Jan 22;19:949-960
pubmed: 33613862
J Exp Med. 2020 Sep 7;217(9):
pubmed: 32510550
Acta Otorhinolaryngol Ital. 2012 Feb;32(1):18-25
pubmed: 22500062
J Clin Invest. 2009 Jun;119(6):1420-8
pubmed: 19487818
Otolaryngol Head Neck Surg. 2013 Aug;149(2):245-51
pubmed: 23585149
PLoS One. 2013 Nov 15;8(11):e80742
pubmed: 24260469
Cancer. 2016 May 1;122(9):1388-97
pubmed: 26969807
Int J Mol Sci. 2010 Sep 20;11(9):3397-412
pubmed: 20957103
Curr Opin Oncol. 2019 May;31(3):146-151
pubmed: 30893146
Blood. 2007 Feb 15;109(4):1692-700
pubmed: 17023574
J Cell Sci. 2005 Mar 1;118(Pt 5):873-87
pubmed: 15713751
J Biol Chem. 1982 Dec 25;257(24):14949-59
pubmed: 7174676
Mol Carcinog. 2015 Oct;54(10):1147-58
pubmed: 24861206
N Engl J Med. 2003 Nov 27;349(22):2091-8
pubmed: 14645636
Int J Mol Sci. 2017 Sep 15;18(9):
pubmed: 28914774
Laryngoscope. 2001 Jun;111(6):1079-87
pubmed: 11404625
Carcinogenesis. 2014 Sep;35(9):2039-46
pubmed: 24760461
Cancer. 2016 Feb 15;122(4):534-45
pubmed: 26554754
Mol Clin Oncol. 2013 Jul;1(4):685-691
pubmed: 24649229
N Engl J Med. 1988 Sep 1;319(9):525-32
pubmed: 2841597
Oncotarget. 2013 Jan;4(1):145-55
pubmed: 23370967
J Clin Invest. 2003 Dec;112(12):1776-84
pubmed: 14679171
Mol Pharmacol. 2019 Aug;96(2):168-179
pubmed: 31175180
Acta Otorrinolaringol Esp. 2012 Jul-Aug;63(4):292-8
pubmed: 22579383
Cancer Biomark. 2020;28(2):181-191
pubmed: 32224526
Curr Opin Oncol. 2020 May;32(3):178-186
pubmed: 32209823
Lancet. 2019 Nov 23;394(10212):1882-1884
pubmed: 31679948
Niger J Clin Pract. 2019 Dec;22(12):1698-1705
pubmed: 31793477